Insider Selling: Heartflow (NASDAQ:HTFL) Insider Sells 9,219 Shares

Heartflow, Inc. (NASDAQ:HTFL) insider Campbell Rogers sold 9,219 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $41.23, for a total value of $380,099.37. Following the completion of the transaction, the insider directly owned 86,459 shares in the company, valued at approximately $3,564,704.57. This represents a 9.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Heartflow Price Performance

NASDAQ HTFL traded up $0.30 during trading hours on Wednesday, reaching $45.53. 2,938,828 shares of the stock traded hands, compared to its average volume of 1,751,769. The stock has a 50 day simple moving average of $30.00 and a two-hundred day simple moving average of $28.05. Heartflow, Inc. has a 1 year low of $20.13 and a 1 year high of $47.23. The company has a market cap of $3.96 billion and a price-to-earnings ratio of -24.88.

Heartflow (NASDAQ:HTFL) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. The firm had revenue of $64.08 million during the quarter. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.The company’s quarterly revenue was up 47.7% on a year-over-year basis. On average, sell-side analysts forecast that Heartflow, Inc. will post -0.82 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on HTFL shares. Robert W. Baird set a $45.00 price target on shares of Heartflow in a research report on Friday, August 14th. Canaccord Genuity Group boosted their price objective on shares of Heartflow from $37.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, August 14th. Piper Sandler reaffirmed an “overweight” rating and issued a $45.00 price objective (up from $38.00) on shares of Heartflow in a research note on Friday, August 14th. William Blair began coverage on shares of Heartflow in a report on Monday, May 4th. They set an “outperform” rating on the stock. Finally, Morgan Stanley lifted their target price on shares of Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a research report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Heartflow has an average rating of “Moderate Buy” and a consensus target price of $43.43.

Hedge Funds Weigh In On Heartflow

Several institutional investors and hedge funds have recently bought and sold shares of HTFL. Caitong International Asset Management Co. Ltd purchased a new position in shares of Heartflow in the fourth quarter worth $27,000. Russell Investments Group Ltd. purchased a new stake in Heartflow during the 4th quarter valued at $45,000. Legal & General Group Plc purchased a new stake in Heartflow during the 3rd quarter valued at $59,000. Essential Partners LLC bought a new stake in Heartflow in the 1st quarter worth $57,000. Finally, Strs Ohio purchased a new position in shares of Heartflow in the fourth quarter valued at about $99,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.